Historical Valuation
Pyxis Oncology Inc (PYXS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.93. The fair price of Pyxis Oncology Inc (PYXS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.76
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Pyxis Oncology Inc (PYXS) has a current Price-to-Book (P/B) ratio of 1.04. Compared to its 3-year average P/B ratio of 1.09 , the current P/B ratio is approximately -4.56% higher. Relative to its 5-year average P/B ratio of 0.86, the current P/B ratio is about 20.61% higher. Pyxis Oncology Inc (PYXS) has a Forward Free Cash Flow (FCF) yield of approximately -101.08%. Compared to its 3-year average FCF yield of -70.60%, the current FCF yield is approximately 43.16% lower. Relative to its 5-year average FCF yield of -71.51% , the current FCF yield is about 41.34% lower.
P/B
Median3y
1.09
Median5y
0.86
FCF Yield
Median3y
-70.60
Median5y
-71.51
Competitors Valuation Multiple
AI Analysis for PYXS
The average P/S ratio for PYXS competitors is 18.19, providing a benchmark for relative valuation. Pyxis Oncology Inc Corp (PYXS.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PYXS
1Y
3Y
5Y
Market capitalization of PYXS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PYXS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PYXS currently overvalued or undervalued?
Pyxis Oncology Inc (PYXS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.93. The fair price of Pyxis Oncology Inc (PYXS) is between NaN to NaN according to relative valuation methord.
What is Pyxis Oncology Inc (PYXS) fair value?
PYXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Pyxis Oncology Inc (PYXS) is between NaN to NaN according to relative valuation methord.
How does PYXS's valuation metrics compare to the industry average?
The average P/S ratio for PYXS's competitors is 18.19, providing a benchmark for relative valuation. Pyxis Oncology Inc Corp (PYXS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Pyxis Oncology Inc (PYXS) as of Jan 10 2026?
As of Jan 10 2026, Pyxis Oncology Inc (PYXS) has a P/B ratio of 1.04. This indicates that the market values PYXS at 1.04 times its book value.
What is the current FCF Yield for Pyxis Oncology Inc (PYXS) as of Jan 10 2026?
As of Jan 10 2026, Pyxis Oncology Inc (PYXS) has a FCF Yield of -101.08%. This means that for every dollar of Pyxis Oncology Inc’s market capitalization, the company generates -101.08 cents in free cash flow.
What is the current Forward P/E ratio for Pyxis Oncology Inc (PYXS) as of Jan 10 2026?
As of Jan 10 2026, Pyxis Oncology Inc (PYXS) has a Forward P/E ratio of -0.87. This means the market is willing to pay $-0.87 for every dollar of Pyxis Oncology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Pyxis Oncology Inc (PYXS) as of Jan 10 2026?
As of Jan 10 2026, Pyxis Oncology Inc (PYXS) has a Forward P/S ratio of 0.00. This means the market is valuing PYXS at $0.00 for every dollar of expected revenue over the next 12 months.